

Ref. No: 1996
Date: 18/08/25
Subject: New biologic and targeted medications - Gastroenterology

REQUEST

Q1. How many patients were treated in July 2025 (or latest available month) by the gastroenterology department with the following biologic drugs?

- Etrasimod
- Filgotinib
- Golimumab
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab (Stelara)
- Ustekinumab Biosimilar
- Vedolizumab

Q2. How many patients were treated in July 2025 (or latest available month) for Crohn's disease with the following biologic drugs?

- Golimumab
- Risankizumab
- Upadacitinib
- Ustekinumab (Stelara)
- Ustekinumab Biosimilar
- Vedolizumab

RESPONSE

Q1. How many patients were treated in July 2025 (or latest available month) by the gastroenterology department with the following biologic drugs?

- Etrasimod **0**
- Filgotinib **6**
- Golimumab **0**
- Mirikizumab **10**
- Ozanimod **<5**
- Risankizumab **12**
- Tofacitinib **9**
- Upadacitinib **14**
- Ustekinumab (Stelara) **8**
- Ustekinumab Biosimilar **113**
- Vedolizumab **61**

Q2. How many patients were treated in July 2025 (or latest available month) for Crohn's disease with the following biologic drugs?

- Golimumab **0**
- Risankizumab **<5**
- Upadacitinib **<5**
- Ustekinumab (Stelara) **<5**
- Ustekinumab Biosimilar **12**
- Vedolizumab **6**